Regenxbio (RGNX) Total Non-Current Liabilities (2018 - 2026)

Regenxbio's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $349.7 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 72.5% year-over-year to $349.7 million; the TTM figure through Dec 2025 stood at $349.7 million (up 72.5% YoY), while the FY2025 annual figure was $349.7 million, up 72.5% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $349.7 million, down from $363.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $366.7 million in Q2 2025, with the low at $178.1 million in Q2 2021.
• The 5-year median for Total Non-Current Liabilities is $249.8 million (2023), against an average of $258.1 million.
• The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities jumped 652.67% in 2021, then plunged 30.95% in 2024.
• Regenxbio's Total Non-Current Liabilities stood at $178.3 million in 2021, then rose by 0.68% to $179.5 million in 2022, then grew by 21.88% to $218.7 million in 2023, then fell by 7.33% to $202.7 million in 2024, then jumped by 72.5% to $349.7 million in 2025.
• Business Quant data shows RGNX's Total Non-Current Liabilities at $349.7 million in Q4 2025, $363.1 million in Q3 2025, and $366.7 million in Q2 2025.